ABSTRACT
Objective To evaluate two treatment schemes of liver protection and choose the optimal radiotherapy using phar‐macoeconomics principle and methods .Methods In‐patients who were diagnosed as decompensated cirrhosis patients and simultaneously conformed to the Chlid‐Pugh graduation of level B‐C during 2010-2012 were chosen .The chosen patients were divided into A ,B and C group separately ,and were treated with the compound prescription of dichloro acetic acid two isopropyl amine inoculation fluid ,the poly‐ene phosphatide acid radical choline inoculation fluid ,and the compound prescription dichloro acetic acid two isopropyl amine inoculation fluid and the polyene phosphatide acid radical choline inoculation fluid .Cost effectiveness analysis was done between group B and C .Re‐sults Treatment time of group B and C was (15 .5 ± 8 .55) d and (12 .13 ± 7 .61) d respectively .The total effectiveness was 50% and 60% respectively and the difference was with non‐statistics significance (P>0 .05) .The total cost was (1 640 .52 ± 905 .26) yuan and (2 576 .51 ± 1 615 .99) yuan respectively .Conclusion Group B was the better treatment scheme .
ABSTRACT
O artigo aborda o uso racional de medicamentos (URM) sob um ponto de vista da economia. O URM, para ser implementado, implica custos e envolve a apropriação de conhecimentos e mudanças de conduta de diversos agentes. A dificuldade na adoção da prática do URM pode estar relacionada a problemas de escassez, assimetria de informação, informação incompleta, incertezas nas decisões clínicas, externalidades, preço-tempo, incentivos para prescritores e dispensadores, preferências dos prescritores e utilidade marginal. Assim, cabe às autoridades sanitárias, entre outras entidades, regular, reduzir e controlar essas falhas que poderão introduzir ineficiências na assistência farmacêutica, bem como produzir riscos à vida humana.
The present article approaches rational drug use (RDU) from the economical point of view. The implementation of RDU implies in costs and involves acquisition of knowledge and behavioral changes of several agents. The difficulties in implementing RDU may be due to shortage problems, information asymmetry, lack of information, uncertain clinical decisions, externalities, time-price, incentives for drug prescribers and dispensers, drug prescriber preferences and marginal utility. Health authorities, among other agencies, must therefore regularize, rationalize and control drug use to minimize inefficiency in pharmaceutical care and to prevent exposing the population to unnecessary health risks.